Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML
This episode discusses updated Phase 3 results of fixed-dose venetoclax-obinutuzumab for previously untreated CLL, dual epi-immunotherapy in classical Hodgkin lymphoma, and a predictive model for treatment failure in CML patients on TKI therapy.